QURE - uniQure N.V.
| Previous Close | 74.61 |
| Open | 74.80 |
| Bid | 74.50 x 900 |
| Ask | 74.50 x 1200 |
| Day's Range | 72.58 - 76.45 |
| 52 Week Range | 21.98 - 82.49 |
| Volume | 804,385 |
| Avg. Volume | 670,318 |
| Market Cap | 2.832B |
| Beta (3Y Monthly) | 1.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.48 |
| Earnings Date | May 30, 2017 - Jun 2, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 84.62 |
- Insider Monkey•3 days ago
Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- GlobeNewswire•5 days ago
uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH)
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 21, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
- Zacks•6 days ago
The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
- Zacks•7 days ago
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.
- Investor's Business Daily•9 days ago
Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst
Gene therapy player Uniqure could head to the auction block, an analyst said Monday as shares of the biotech company popped. He also said Roche's plan to buy Spark Therapeutics could falter.
- Bloomberg•9 days ago
Gene-Therapy Firm UniQure Explores Options Including Sale
(Bloomberg) -- UniQure NV is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy, people with knowledge of the matter said. The shares jumped.The biotechnology company is working with advisers as it weighs options including a sale or partnerships, according to the people, who asked not to be identified because the information is private. UniQure’s shares have risen more than 151% in New York this year, giving it a market value of about $2.7 billion.UniQure shares rose as much as 9.2% to $79.20 in New York, the stock’s highest-ever intraday price.Major pharmaceutical firms have been pursuing gene-therapy companies that promise to treat rare, debilitating diseases by correcting DNA flaws. While the field has yet to deliver a blockbuster, the promise of dramatic cures carrying multimillion-dollar price tags has triggered a flurry of deal activity. Cantor Fitzgerald LP said in February that UniQure “could be next” and may attract interest from large-cap companies such as Novo Nordisk A/S, Pfizer Inc. and Sanofi.A deal with UniQure would bring access to a pipeline of experimental treatments for hemophilia, Huntington’s disease and other disorders. The company is incorporated in the Netherlands, with about 200 employees spread between Amsterdam and Lexington, Massachusetts, according to its website.Read more: After $1 Million Drug Flop, UniQure Revives in Gene TherapyUniQure shares surged earlier this month after it canceled plans to attend Goldman Sachs Group Inc.’s annual health-care conference. The company said it pulled out due to a conflict with Chief Executive Officer Matt Kapusta’s schedule.No final decisions have been made, and there’s no certainty the deliberations will lead to a transaction, the people said. A representative for UniQure declined to comment.Biogen Inc. agreed earlier this year to buy Nightstar Therapeutics Plc, and Pfizer bought a stake in Vivet Therapeutics. Roche Holding AG agreed in February to acquire Spark Therapeutics Inc. for $4.8 billion, following Novartis AG’s $8.7 billion purchase of AveXis Inc. last year.UniQure developed Glybera, the first gene therapy approved for sale in Europe, though the $1 million treatment had disappointing sales and the company said it wouldn’t renew its marketing authorization in 2017. Since then, the company has focused on hemophilia treatments.Gene therapy deals are starting to face some scrutiny from regulators. Earlier this month, the U.S. Federal Trade Commission asked Roche and Spark for more information as part of its review of their pending deal. The latest FTC request came after the agency said in April it would need more time to examine the transaction.(Updates with opening shares in the third paragraph.)\--With assistance from James Paton and Ruth David.To contact the reporters on this story: Manuel Baigorri in Hong Kong at mbaigorri@bloomberg.net;Dinesh Nair in London at dnair5@bloomberg.net;Ed Hammond in New York at ehammond12@bloomberg.netTo contact the editors responsible for this story: Dinesh Nair at dnair5@bloomberg.net, Ben Scent, Amy ThomsonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- TheStreet.com•9 days ago
UniQure Jumps on Report It's Exploring a Possible Sale
jumped Monday after a report said the biotechnology company was exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy. UniQure is working with advisers as it weighs options including a sale or partnerships, Bloomberg reported, citing people with knowledge of the matter. UniQure developed Glybera, the first gene therapy approved for sale in Europe, though the $1 million treatment had disappointing sales and the company said it wouldn't renew its marketing authorization in 2017.
- Zacks•15 days ago
Is the Options Market Predicting a Spike in uniQure (QURE) Stock?
Investors need to pay close attention to uniQure (QURE) stock based on the movements in the options market lately.
- MarketWatch•21 days ago
AMD and 3 more momentum stocks to watch
These four stocks in the high-momentum technology, biotech and mining areas are on the move. Advanced Micro Devices (AMD) leapt $1.99 to $29.57 on 107 million shares Tuesday. On Monday the chip maker announced a deal to license its custom graphics intellectual property to Samsung for use in mobile devices.
- Simply Wall St.•21 days ago
An Intrinsic Calculation For uniQure N.V. (NASDAQ:QURE) Suggests It's 29% Undervalued
In this article we are going to estimate the intrinsic value of uniQure N.V. (NASDAQ:QURE) by taking the expected...
- Zacks•22 days ago
uniQure (QURE) Jumps: Stock Rises 8.9%
uniQure (QURE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- GlobeNewswire•26 days ago
uniQure to Participate in Multiple Upcoming Industry Conferences
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 31, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
- InvestorPlace•27 days ago
3 Top Gene Therapy Stocks That Could Soar
Thanks to advances in technology and gene sequencing, gene therapy has gone from science fiction to science fact. By either adding new genes to fight faulty ones, replacing/editing missing/broken prices or actually "turning off" the genes causing problems, gene therapy has the potential to change the game when it comes to biotech stocks and healthcare.That's great news, as there are more than 10,000 different disorders and diseases caused by faulty genes.With the FDA launching several fast-track programs for gene therapies last summer, the biotech stocks that specialize in these cutting-edge treatments could see their drugs hit the market that much faster. And yet, the recent market sell-off has caused many of the biotech stocks looking at gene therapy to crater. Given their game-changing potential, these days many stocks in the sector could be considered bargains.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSome more than others. * 7 Stocks to Sell Amid an Escalating Trade War Which gene-therapy biotech stocks have great potential to soar over the long haul? Here are three stocks to buy that could do just that. Gene Therapy Stocks to Buy: CRISPR Therapeutics (CRSP)Source: Shutterstock Clustered Regularly Interspaced Short Palindromic Repeats is a mouthful to say, which is why scientists have shortened it to just CRISPR. CRISPR is the latest method of gene editing and offers cheaper, simpler and faster slicing and dicing of genes. As its name implies, CRISPR Therapeutics (NASDAQ:CRSP) uses the technique.CRSP stock is targeting blood diseases such as beta-thalassemia and sickle cell disease- which are caused by the same mutation. The beauty of this is that the biotech has been able to move ahead at the same time for both indications. Partnering with biotech giant Vertex Pharmaceuticals (NASDAQ:VRTX), CRSP's lead candidate -- CTX001 -- started phase 1 clinical trials this past February. This trial marks the first time in history that a human trial for a CRISPR-based product has been conducted.Naturally, a lot is riding on the trial- especially with the drug winning FDA fast track status. If results are even somewhat positive, CRSP stock could surge higher.But CTX001 isn't the only drug in CRSP's arsenal. The firm is working one several oncology products as well as new gene editing therapies for muscular dystrophy and cystic fibrosis. These drugs could provide plenty of upside as well down the road.In the end, if you're looking for biotech stocks to buy that are looking at gene therapy, CRISPR Therapeutics could be a major star. uniQure NV (QURE)Source: Shutterstock When it comes to biotech stocks, uniQure (NASDAQ:QURE) is gene therapy royalty. That's because the firm actually created and launched the very first successful gene therapy back in 2012. However, due to the cost of the drug, it was never prescribed. But QURE has turned that successful approval into a platform for further successful development.This includes the biotech stock's latest work for hemophilia. QURE has seen great success with its gene therapy program for the blood disorder. After seeing amazing initial results, QURE has moved its top hemophilia medication -- AMT-061 -- into phase I/IIb trials. This news sent the clinical stage biotech stock up more than 34%. Given its past history of navigating the gene therapy waters to approval, QURE could have another hit on its hand.Elsewhere, the firm has started trials for the first gene therapy targeting Huntington's disease and has gene therapies for congestive heart failure in pipelines. All of these are much more "popular" issues and should help QURE actually see prescription growth if successful. * 7 Stocks to Buy for June Like most clinical-stage biotech stocks, QURE is a gamble. But it's a more calculated risk than most given its history and how great its previous results were. Voyager Therapeutics (VYGR)Source: Shutterstock When it comes to clinical stage biotech stocks, it pays to look at partnerships. For gene therapy play Voyager Therapeutics (NASDAQ:VYGR), partnerships include biotech giant AbbVie (NYSE:ABBV), neurological specialist Neurocrine Biosciences (NASDAQ:NBIX) and major pharma stock Sanofi (NASDAQ:SNY). All three of those major players have provided VYGR with some major cash infusions to develop its technology and gene therapy applications. Most clinical biotech stocks would kill to have more than $360 million in cash on their balance sheets.That cash will provide it plenty of working capital to develop its lucrative gene therapy portfolio.And lucrative it will be. VYGR is targeting Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease and Alzheimer's disease. These are some of the hardest diseases to crack and winners here will be massive achievements. It seems that Voyager may just get there.So far, results for the firm's tech have been pretty positive, which could explain all the major partnerships. Back in March, Voyager announced that its initial trial for VY-AADC demonstrated improvement in clinical measures for Parkinson's Disease. This success prompted VYGR to start phase II trials -- with results coming in mid-2020. Meanwhile, the firm is moving forward with initial trials with its other partners and developing a robust pipeline. With ample cash, VYGR has plenty of time to get these therapies through testing. Fast track designation from the FDA doesn't hurt either.All in all, VYGR represents a great gene therapy play thanks to its leading partners. Clearly, they see the good in the biotech stocksAt the time of writing, Aaron Levitt was long CRSP and VYGR stock More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Sell Amid an Escalating Trade War * 5 REITs to Buy While They're Dirt Cheap * The Only 3 Marijuana Stocks You Need to Own Compare Brokers The post 3 Top Gene Therapy Stocks That Could Soar appeared first on InvestorPlace.
- GlobeNewswire•last month
uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 22, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the issuance of two new patents covering AMT-130, the Company’s gene therapy candidate for the treatment of Huntington’s disease. AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette, encoding a microRNA that non-selectively lowers or knocks-down human huntingtin protein in Huntington’s disease patients. The U.S. Patent and Trademark Office issued U.S. Patent 10,174,321 on January 8, 2019 and the European Patent Office issued EP 3237618 on May 22, 2019.
- Investor's Business Daily•2 months ago
This Gene Therapy Stock Is Nearing A Breakout On Its Hemophilia B Study
UniQure stock approached a breakout Friday after its experimental gene therapy showed improving promise in hemophilia B treatment. Shares are consolidating with a buy point at 69.70.
- Simply Wall St.•2 months ago
uniQure N.V. (NASDAQ:QURE) Insiders Have Been Selling
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- GlobeNewswire•2 months ago
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
~ Increases in FIX Activity Sustained at up to 57% of Normal, with Mean FIX of 47% of Normal at Six Months After Administration ~ ~ None of the Patients Received Factor.
- GlobeNewswire•2 months ago
uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting
The abstract entitled, “Development of an AAV-based microRNA Gene Therapy for Treating Spinocerebellar Ataxia Type 3,” is being recognized by the American Academy of Neurology for dual oral and poster presentations during its annual meeting taking place this week in Philadelphia, PA. Spinocerebellar Ataxia Type 3, also known as Machado-Joseph disease, is caused by a CAG-repeat expansion in the ATXN3 gene that results in an abnormal form of the toxic protein ataxin-3, leading to brain degeneration that results in movement disorders, rigidity, muscular atrophy and paralysis.
- Insider Monkey•2 months ago
Did Hedge Funds Drop The Ball On Uniqure NV (QURE) ?
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
- GlobeNewswire•2 months ago
uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 02, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, will present today new preclinical data on its gene therapy candidates AMT-180 for the treatment of hemophilia A and AMT-190 for the treatment of Fabry disease. Hemophilia A is an X-linked bleeding disorder resulting from a deficiency in coagulation Factor VIII that serves as a cofactor for Factor IX in the activation of the coagulation cascade. About 30 percent of the hemophilia A patient population develops inhibitors to Factor VIII over the course of the disease.
- Associated Press•2 months ago
UniQure: 1Q Earnings Snapshot
The Amsterdam-based company said it had a loss of 74 cents per share. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for ...
- GlobeNewswire•2 months ago
uniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress
~ Presented Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B Demonstrating Increases in FIX Activity Sustained at up to 51% of Normal at 12.
- GlobeNewswire•2 months ago
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 15, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
